APP and amyloidosis: Most recently the gantenerumab Aβ antibody was shown preferentially to bind aggregated brain Aβ and in APP/PS-1 mice, to reduce or halt Aβ plaque formation [57]; however, the Phase 3 clinical trial, in early stage symptomatic patients with evidence of amyloid, was halted in December 2014.